DE60142684D1 - Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen - Google Patents

Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen

Info

Publication number
DE60142684D1
DE60142684D1 DE60142684T DE60142684T DE60142684D1 DE 60142684 D1 DE60142684 D1 DE 60142684D1 DE 60142684 T DE60142684 T DE 60142684T DE 60142684 T DE60142684 T DE 60142684T DE 60142684 D1 DE60142684 D1 DE 60142684D1
Authority
DE
Germany
Prior art keywords
cells
autoreactive
blocking
destruction
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142684T
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Xue-Feng Bai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Application granted granted Critical
Publication of DE60142684D1 publication Critical patent/DE60142684D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
DE60142684T 2000-03-29 2001-03-29 Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen Expired - Lifetime DE60142684D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19281400P 2000-03-29 2000-03-29
PCT/US2001/040390 WO2001072325A1 (en) 2000-03-29 2001-03-29 Methods of blocking tissue destruction by autoreactive t cells

Publications (1)

Publication Number Publication Date
DE60142684D1 true DE60142684D1 (de) 2010-09-09

Family

ID=22711138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60142684T Expired - Lifetime DE60142684D1 (de) 2000-03-29 2001-03-29 Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen

Country Status (8)

Country Link
EP (1) EP1267909B1 (de)
JP (1) JP2004500110A (de)
AT (1) ATE475428T1 (de)
AU (2) AU5979201A (de)
CA (1) CA2404340C (de)
DE (1) DE60142684D1 (de)
DK (1) DK1267909T3 (de)
WO (1) WO2001072325A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
PT3260128T (pt) * 2010-04-28 2020-10-22 Oncolmmune Inc Utilização médica de cd24 solúvel
MX2015000428A (es) * 2012-07-13 2015-03-12 Univ Pennsylvania Composiciones y metodos para regular celulas t car.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
EP3215539A4 (de) * 2014-11-06 2018-05-23 Children's Research Institute, Children's National Immuntherapeutika für krebs und autoimmunkrankheiten
EP3292144B1 (de) * 2015-05-07 2020-08-26 OncoImmune, Inc. Verwendung von cd24 zur senkung des gehalts von lipoproteincholesterin mit geringer dichte
US10639350B2 (en) 2015-08-10 2020-05-05 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using CD24
KR20180120145A (ko) * 2016-02-02 2018-11-05 온코이뮨, 아이앤씨. 렙틴-결핍 병태를 치료하기 위한 cd24 단백질의 용도
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
TW201900671A (zh) * 2017-05-15 2019-01-01 美商昂科免疫公司 使用可溶性cd24進行神經保護及髓鞘再生的方法
TW202016139A (zh) 2018-06-13 2020-05-01 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途

Also Published As

Publication number Publication date
ATE475428T1 (de) 2010-08-15
CA2404340C (en) 2012-10-16
AU5979201A (en) 2001-10-08
EP1267909A4 (de) 2006-05-03
WO2001072325A1 (en) 2001-10-04
JP2004500110A (ja) 2004-01-08
CA2404340A1 (en) 2001-10-04
EP1267909A1 (de) 2003-01-02
AU2001259792B2 (en) 2005-12-22
DK1267909T3 (da) 2010-11-08
WO2001072325A9 (en) 2003-02-20
EP1267909B1 (de) 2010-07-28

Similar Documents

Publication Publication Date Title
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
DE60142684D1 (de) Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen
Jones et al. Histogenesis of Kaposi's sarcoma in patients with and without acquired immune deficiency syndrome (AIDS).
Thayaparan et al. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
JPH04507195A (ja) 腫瘍壊死因子結合リガンド
KR927003816A (ko) Cd3에 대한 항체
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
McComb et al. Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue.
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
FI973120A (fi) Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
ES2527717T3 (es) Método para producir una proteína de fusión de glucoproteína vi-Fc
ES2102007T3 (es) Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
DE69430450D1 (de) Zell- und serum- proteinanker und konjugate
ATE11372T1 (de) Von vernetztem fibrin abgeleitete radiomarkierte peptide zur bestimmung von thrombi und die dieselben enthaltenden injektierbaren zusammensetzungen.
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
Morris et al. Association of Thy-1 cell surface differentiation antigen with certain connective tissues in vivo
CN105744944A (zh) 免疫系统调节器
DE68925226D1 (de) Monoklonale Antikörper
Zhuang et al. Robo4 vaccines induce antibodies that retard tumor growth
ATE252637T1 (de) Antikörper gegen lymphozyten-assoziiertes zelloberflächenprotein
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
AR003941A1 (es) Anticuerpos monoclonales humanos neutralizadores de hiv-1
Moolten et al. Induction of antibodies against carcinogenic polycyclic aromatic hydrocarbons
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen